Page 29 - Heca News Today

Bristol Myers Squibb said on Wednesday evening its CEO Giovanni Caforio would step down in November and will be replaced by current Chief Commercialization Officer Chris Boerner, as the drugmaker contends with increasing generic competition for its top-selling drugs.

Doctor Oleg Marchenko never knows what he will find when he visits villages retaken by Ukrainian forces in the east of the country last autumn. Mines lie scattered around and often there are no medical facilities left.

AstraZeneca on Thursday beat expectations for first-quarter profit and revenue, as buoyant sales of cancer drug Imfinzi and strong demand for its roster of drugs in emerging markets helped to offset dwindling COVID product sales.

Chinese spirit maker ZJLD Group's shares ended down 18% on their first day of trading on Thursday, dampening hopes that a positive debut for the largest new share sale in Hong Kong in 2023 could spark a rush of listings in the second half.

China Evergrande Group will get a signal on Thursday of the level of creditor backing for its offshore debt restructuring proposal, with investors to be given an incentive for early support.

Johnson & Johnson said on Thursday it has agreed to retain all talc-related liabilities arising from litigation in the United States and Canada and will "indemnify" newly formed consumer health unit Kenvue for all costs.

Embattled property developer China Evergrande Group said on Thursday it would extend the deadline for receiving an incentive for its debt restructuring proposal to May 18 as the company disclosed levels of support from offshore debt-holders for its proposal.

AbbVie Inc on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker's attempts to cushion the blow to sales from fresh competition for its flagship arthritis drug Humira.

The tech-heavy Nasdaq led a Wall Street rally on Thursday as a strong update from Meta Platforms outweighed concerns over slowing U.S. economic growth.

Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co .